TAE Life Sciences (TLS), a prominent developer of boron neutron capture therapy (BNCT) technology and related boron target drugs, and Stella Pharma, the developer of the boronophenylalanine (BPA) drug Steboronine® for BNCT, have announced a strategic collaboration. This partnership focuses on developing, commercializing, and expanding BNCT using BPA within the United States and European markets. Steboronine® represents a significant advancement, being the first and only clinically approved boron drug for BNCT. Japan led the way in approving BNCT for head and neck cancer treatment utilizing Stella Pharma’s BPA drug. Stella Pharma, a leading BPA producer and supplier, is partnering with TAE Life Sciences to broaden BNCT adoption globally.
The collaboration encompasses extensive international cooperation in BNCT and BPA development and commercialization across the US and Europe, with clinical trials projected to commence in 2026. TLS will act as the exclusive commercial partner for Stella Pharma’s BPA in these regions, significantly increasing BNCT’s availability outside Asia. This partnership represents a substantial step in making BNCT a viable cancer treatment option for patients worldwide.
Both companies are also dedicated to supporting BNCT equipment vendors globally in implementing BPA-based BNCT treatments. By fostering partnerships within the BNCT ecosystem, TLS and Stella Pharma aim to enhance BNCT’s clinical reach. Their shared objective is to improve treatment for recurrent head and neck cancers and advance clinical studies for other cancers, including brain, skin, breast, esophagus, and lung. This alliance is a key milestone in expanding BPA-based BNCT treatments beyond Asia, aiming to deliver this advanced cancer treatment to patients globally.
Beyond the immediate collaborative efforts, Stella Pharma and TAE Life Sciences share a long-term vision of advancing BNCT for challenging cancers. They are committed to exploring further collaborative opportunities, accelerating innovation, expanding treatment options, and improving outcomes for cancer patients worldwide. This partnership symbolizes a significant commitment to progress in the fight against cancer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
